Alterations in daily sequencing of axitinib and fractionated radiotherapy do not affect tumor growth inhibition or pathophysiological response

Radiation Research

Volumn 171, Issue 5, 2009, Pages 606-614

  Fenton, Bruce M ^a   Paoni, Scott F ^a  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AXITINIB; VASCULOTROPIN RECEPTOR; IMIDAZOLE DERIVATIVE; INDAZOLE DERIVATIVE; PROTEIN KINASE INHIBITOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BASEMENT MEMBRANE; CANCER INHIBITION; CANCER RADIOTHERAPY; CONTROLLED STUDY; HUMAN; HUMAN CELL; HYPOXEMIA; MOUSE; NONHUMAN; PATHOPHYSIOLOGY; PERICYTE; PRIORITY JOURNAL; PROSTATE CANCER; RADIATION DOSE FRACTIONATION; RADIATION PROTECTION; RADIOSENSITIVITY; TUMOR GROWTH; TUMOR VASCULARIZATION; TUMOR XENOGRAFT; DRUG EFFECT; MALE; MULTIMODALITY CANCER THERAPY; NEOPLASM; PATHOLOGY; RADIATION EXPOSURE; TUMOR CELL LINE;

BASEMENT MEMBRANE; CELL LINE, TUMOR; COMBINED MODALITY THERAPY; DOSE FRACTIONATION; HUMANS; IMIDAZOLES; INDAZOLES; MALE; NEOPLASMS; PERICYTES; PROTEIN KINASE INHIBITORS;

EID: 67650683732     PISSN: 00337587     EISSN: None     Source Type: Journal    
DOI: 10.1667/RR1595.1     Document Type: Article

References (26)

1. R. K. Jain, Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 307, 58-62 (2005).
2. L. E. Benjamin, D. Golijanin, A. Itin, D. Pode and E. Keshet, Selective ablation of immature blood vessels in established human tumors follows vascular endothelial growth factor withdrawal. J. Clin. Invest. 103, 159-165 (1999).
3. F. Winkler, S. V. Kozin, R. T. Tong, S. S. Chae, M. F. Booth, I. Garkavtsev, L. Xu, D. J. Hicklin, D. Fukumura and R. K. Jain, Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation; Role of oxygenation, angiopoietin-1, and matrix metalloproteinases. Cancer Cell 6, 553-563 (2004).
4. D. H. Gorski, M. A. Beckett, N. T. Jaskowiak, D. P. Calvin, H. J. Mauceri, R. M. Salloum, S. Seetharam, A. Koons, D. M. Hari and R. R. Weichselbaum, Blockade of vascular endothelial growth factor stress response increases the antitumor effects of ionizing radiation. Cancer Res. 59, 3374-3378 (1999).
5. C. Cao, J. M. Albert, L. Geng, P. S. Ivy, A. Sandler, D. H. Johnson and B. Lu, Vascular endothelial growth factor tyrosine kinase inhibitor AZD2171 and fractionated radiotherapy in mouse models of lung cancer. Cancer Res. 66, 11409-11415 (2006).
6. B. M. Fenton and S. F. Paoni, The addition of AG-013736 to fractionated radiation improves tumor response without functionally normalizing the tumor vasculature. Cancer Res. 67, 9921-9928 (2007).
7. G. Wickman, M. Hallin, R. Dillon, K. Amundson, A. Acena, M. Grazzini, M. Herrmann, S. Vekich, M. McTigue and D. Hu-Lowe, Further characterization of the potent VEGF/PDGF receptor tyrosine kinase inhibitor, AG-013736, in preclinical tumor models for its antiangiogenesis and antitumor activity. Proc. Am. Assoc. Cancer Res. 44, A3780 (2003).
8. D. D. Hu-Lowe, H. Y. Zou, M. L. Grazzini, M. E. Hallin, G. R. Wickman, K. Amundson, J. H. Chen, D. A. Rewolinski, S. Yamazaki and S. L. Bender, Nonclinical antiangiogenesis and antitumor activities of axitinib (AG-013736), an oral, potent, and selective inhibitor of vascular endothelial growth factor receptor tyrosine kinases 1 to 3. Clin. Cancer Res. 14, 7272-7283 (2008).
9. M. J. Trotter, D. J. Chaplin and P. L. Olive, Use of a carbocyanine dye as a marker of functional vasculature in murine tumours. Br. J. Cancer 59, 706-709 (1989).
10. 2 saturation measurements. Br. J. Cancer 79, 464-471 (1999).
11. B. M. Fenton, E. M. Lord and S. F. Paoni, Effects of radiation on tumor intravascular oxygenation, vascular configuration, hypoxic development, and survival. Radiat. Res. 155, 360-368 (2001).
12. E. M. Lord, L. Harwell and C. J. Koch, Detection of hypoxic cells by monoclonal antibody recognizing 2-nitroimidazole adducts. Cancer Res. 53, 5721-5726 (1993).
13. S. Song, A. J. Ewald, W Stallcup, Z. Werb and G. Bergers, PDGFRβ + perivascular progenitor cells in tumours regulate pericyte differentiation and vascular survival. Nat. Cell Biol. 7, 870-879 (2005).
14. B. M. Fenton, S. F. Paoni and I. Ding, Effect of VEGF receptor-2 antibody on vascular function and oxygenation in spontaneous and transplanted tumors. Radiother. Oncol. 72, 221-230 (2004).
15. T. Inai, M. Mancuso, H. Hashizume, F. Baffert, A. Haskell, P. Baluk, D. D. Hu-Lowe, D. R. Shalinsky, G. Thurston and D. M. McDonald, Inhibition of vascular endothelial growth factor (VEGF) signaling in cancer causes loss of endothelial fenestrations, regression of tumor vessels, and appearance of basement membrane ghosts. Am. J. Pathol. 165, 35-52 (2004).
16. C. G. Willett, Y. Boucher, E. di Tomaso, D. G. Duda, L. L. Munn, R. T. Tong, D. C. Chung, D. V. Sahani, S. P. Kalva and R. K. Jain, Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat. Med. 10, 145-147 (2004).
17. H. Hurwitz, L. Fehrenbacher, W. Novotny, T. Cartwright, J. Hains-worth, W. Heim, J. Berlin, A. Baron, S. Griffing and F. Kabbinavar, Bevacizumab plus irinotecan, fluorouracil, and leucovorin for meta-static colorectal cancer. N. Engl. J. Med. 350, 2335-2342 (2004).
18. A. J. Schueneman, E. Himmelfarb, L. Geng, J. Tan, E. Donnelly, D. Mendel, G. McMahon and D. E. Hallahan, SU11248 maintenance therapy prevents tumor regrowth after fractionated irradiation of mu-rine tumor models. Cancer Res. 63, 4009-4016 (2003).
19. A. Abdollahi, M. Li, G. Ping, C. Plathow, S. Domhan, F. Kiessling, L. B. Lee, G. McMahon, H. J. Grone and P. E. Huber, Inhibition of platelet-derived growth factor signaling attenuates pulmonary fibrosis. J. Exp. Med. 201, 925-935 (2005).
20. C. Nieder, N. Wiedenmann, N. Andratschke and M. Molls, Current status of angiogenesis inhibitors combined with radiation therapy. Cancer Treat. Rev. 32, 348-3 (2006).
21. R. Murata, Y. Nishimura and M. Hiraoka, An antiangiogenic agent (TNP-470) inhibited reoxygenation during fractionated radiotherapy of murine mammary carcinoma. Int. J. Radiat. Oncol. Biol. Phys. 37, 1107-1113 (1997).
22. P. E. Huber, M. Bischof, J. Jenne, S. Heiland, P. Peschke, R. Saffrich, H. J. Grone, J. Debus, K. E. Lipson and A. Abdollahi, Trimodal cancer treatment: beneficial effects of combined antiangiogenesis, radiation, and chemotherapy. Cancer Res. 65, 3643-3655 (2005).
23. D. Zips, M. Krause, F. Hessel, J. Westphal, K. Bruchner, W. Eicheler, A. Dorfler, R. Grenman, C. Petersen and M. Baumann, Experimental study on different combination schedules of VEGF-receptor inhibitor PTK787/ZK222584 and fractionated irradiation. Anticancer Res. 23, 3869-3876 (2003).
24. S. Ning, D. Laird, J. M. Cherrington and S. J. Knox, The antiangi-ogenic agents SU5416 and SU6668 increase the antitumor effects of fractionated irradiation. Radiat. Res. 157, 45-51 (2002).
25. K. J. Williams, B. A. Telfer, S. Brave, J. Kendrew, L. Whittaker, I. J. Stratford and S. R. Wedge, ZD6474, a potent inhibitor of vascular endothelial growth factor signaling, combined with radiotherapy: schedule-dependent enhancement of antitumor activity. Clin. Cancer Res. 10, 8587-8593 (2004).
26. R. P. Dings, M. Loren, H. Heun, E. McNiel, A. W. Griffioen, K. H. Mayo and R. J. Griffin, Scheduling of radiation with angiogenesis inhibitors anginex and Avastin improves therapeutic outcome via vessel normalization. Clin. Cancer Res. 13, 3395-3402 (2007).